Early ctDNA Testing Provides Another Tool for Predicting Survival Outcomes With Tebentafusp in Metastatic Uveal Melanoma

The incorporation of circulating tumor DNA (ctDNA) testing into standard practice for patients with metastatic uveal melanoma receiving tebentafusp-tebn (Kimmtrak) may provide a more accurate assessment of the agent’s efficacy compared with radiographic response, and better inform the decision to continue or discontinue treatment, according to research recently presented at the 2023 American Association of Cancer Research (AACR) conference by Ryan J. Sullivan, MD, associate professor of medicine at Harvard Medical School, associate director of the Melanoma Program at Massachusetts General Cancer and Co-Chair of the MRF Breakthrough Consortium. To learn more read an interview with Dr. Sullivan, click here.